Titan seeks approval for Probuphine

Titan Pharmaceuticals Inc. (OTCBB:TTNP) submitted an NDA to FDA for Probuphine buprenorphine to treat opioid dependence. The company requested Priority Review for the application. The NDA was submitted under the section 505(b)(2) of the Food, Drug and Cosmetic Act, which allows sponsors to reference data on safety and efficacy from the scientific literature or from previously approved products. ...